STEADY
Prospective, randomized, open-label Phase III clinical trial with blinded endpoint assessing the efficacy and safety of ciclosporin and methotrexate in children and adolescents with moderate to severe atopic dermatitis.
Prospective, randomized, open-label Phase III clinical trial with blinded endpoint assessing the efficacy and safety of ciclosporin and methotrexate in children and adolescents with moderate to severe atopic dermatitis.